A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00615199. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Safety And Efficacy Of CP-690,550 In Subjects With Moderate To Severe Crohn's Disease.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo (inactive drug).
Study identification
- NCT ID
- NCT00615199
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2008 (Type not available)
- Primary completion
- Oct 2009 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- Jan 25, 2013
2008 – 2009
United States locations
- U.S. sites
- 39
- U.S. states
- 19
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | Mobile | Alabama | 36617 | — |
| Pfizer Investigational Site | Boulder | Colorado | 80304 | — |
| Pfizer Investigational Site | Lakewood | Colorado | 80215 | — |
| Pfizer Investigational Site | Wheat Ridge | Colorado | 80033 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20006 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33428 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33442 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33486 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33496 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32605 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32607 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32207 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32256 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33709 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60637 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67208 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | Chevy Chase | Maryland | 20815 | — |
| Pfizer Investigational Site | Towson | Maryland | 21204 | — |
| Pfizer Investigational Site | Troy | Michigan | 48098 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | Mexico | Missouri | 65265 | — |
| Pfizer Investigational Site | Great Neck | New York | 11021 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28209 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28210 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28211 | — |
| Pfizer Investigational Site | Salisbury | North Carolina | 28144 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45415 | — |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15243 | — |
| Pfizer Investigational Site | Upper Saint Clair | Pennsylvania | 15241 | — |
| Pfizer Investigational Site | Bristol | Tennessee | 37620 | — |
| Pfizer Investigational Site | Kingsport | Tennessee | 37660 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Dallas | Texas | 75235 | — |
| Pfizer Investigational Site | Dallas | Texas | 75390-8887 | — |
| Pfizer Investigational Site | Seattle | Washington | 98195 | — |
| Pfizer Investigational Site | Charleston | West Virginia | 25304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00615199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 25, 2013 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.